NLRP3 and infection: In addition, a recent clinical trial concluded that NLRP3 inflammasome activation by antibody-mediated SARS-CoV-2 in monocytes/macrophages triggers inflammatory cell death and terminates the infection but causes systemic inflammation that contributes to COVID-19 pathogenesis [48].